The Yale University School Of Medicine is teaming with a Portland-based medical marijuana grower to conduct the first state-approved study of medical marijuana’s impact on stress and mental health.

Yale and CT Pharmaceutical Solutions Inc. (CTPharma) on Friday announced they will conduct a phase-one study on the impact of various medicinal marijuana strains commonly used to alleviate pain and stress. Other conditions may also be examined in the study including post traumatic stress disorder, or PTSD, and opioid-replacement, according to Yale.

Yale said the “groundbreaking” clinical study is the first approved by the state Department of Consumer Protection’s (DCP) medical marijuana research program to study stress and mental-health related issues.

The new study will build on CTPharma’s current work involving human subjects, which began with Yale’s Dr. Rajita Sinha in 2016.

In 2017, Sinha in collaboration with CTPharma received approval from the Food and Drug Administration (FDA) for an investigational New Drug application to examine how medical marijuana products effect subjective and physiological responses to stress and pain.

“With increasing levels of use of medical marijuana products in the U.S. today, it is imperative that we understand the science of how these products are working to alleviate patient symptoms,” Sinha said in a news release. [Read more at Hartford Business Journal]